Gilead Sciences (GILD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Gilead Sciences

NasdaqGS•Healthcare•Drug Manufacturers - General

$170.33-0.35(<0.01%)Pre-market

Market Cap

$208.00B

P/S

6.7x

P/B

16.0x

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

How this company scores

AverageMetricSide Score: 56/100

Strongest: Cash & Earnings Quality (25/25); weakest: Balance Sheet & Red Flags (9/25).

Profitability9/25

Growth13/25

Balance Sheet & Red Flags9/25

Cash & Earnings Quality25/25

Strengths

Rising free cash flowCash-backed earningsConsistent free cash flowConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 18.4x5y range 14.8x – 823.2x

Currently near its 18-quarter median.

P/S · 6.7x5y range 2.7x – 6.7x

Currently above its 20-quarter median.

P/B · 16.0x5y range 3.8x – 16.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 120.4% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Leverage Risk

Watch

Debt-to-equity has risen 77.7% recently — increasing financial risk even if the current ratio is manageable.

Price & Volume

Market Cap $208.00B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $30.99B
Q. Revenue: $8.30B
TTM EBITDA: $-2.36B
TTM Op. Income: $-2.36B
Q. Op. Income: $3.46B
TTM Net Income: $-3.86B
Q. Net Income: $2.43B
EPS: $1.96
Shares Out.: $1.24B

$30.99B in TTM revenue grew 6.5% YoY, reaching $8.30B last quarter. TTM EBITDA of $-2.36B and TTM operating income of $-2.36B show growth is flowing through to the bottom line. However, net income is negative at $3.86B — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 6 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 81.1%
EBITDA Margin: 41.7%
Op. Margin: 41.7%
Net Margin: 29.3%

Op. margin of 41.7% is down 1.1% YoY — costs are rising relative to revenue. Net margin at 29.3% and gross margin of 81.1% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 3% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 6.7x
P/B Ratio: 16.0x

P/S of 6.7x and P/B of 16.0x. Across the last 6 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $51.41B
Cash: $6.44B
Long-Term Debt: $23.82B
Book Value: $13.04B
D/E Ratio: 1.8
Debt/EBITDA: 6.9

With $51.41B in assets and $23.82B in long-term debt, D/E is 1.8and book value is $13.04B — moderate leverage. Over the past year, debt/equity is up 78% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $5.04B
TTM Free Cash Flow: $13.78B
FCF Margin: 44.5%
FCF / Net Income: -3.6

TTM FCF of $13.78B on $5.04B in operating cash flow. The FCF / Net Income ratio of -3.6x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.